Sarclisa
Payments companies reported to CMS as associated with Sarclisa. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Sarclisa, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Sarclisa
These are the largest totals companies reported as associated with Sarclisa. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ariel Grajales Cruz | Tampa, FL | Hematology & Oncology | $300,982.76 |
| William Bensinger | Lakewood, WA | Medical Oncology | $154,623.74 |
| Edward Pearson | Dallas, TX | Hematology & Oncology | $139,606.23 |
| Cristina Gasparetto | Durham, NC | Infectious Disease | $136,213.35 |
| Joshua Richter | New York, NY | Medical Oncology | $135,669.96 |
| Cristiana Chase | Durham, NC | $122,476.17 | |
| Hakan Kaya | Spokane, WA | Medical Oncology | $101,106.22 |
| James Berenson | West Hollywood, CA | $96,430.76 | |
| Tulio Rodriguez | Zion, IL | Hematology & Oncology | $94,678.17 |
| Raymond Thertulien | Charlotte, NC | Hematology (Internal Medicine) | $91,583.88 |
Prescribed Sarclisa?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.